Mobile

Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics...

Update Il y a 4 ans
Reference: EUCTR2006-005588-24

Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of omalizumab

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate safety and tolerability of omalizumab in mild and moderate asthmatics with baseline IgE/body-weight combinations above those defined in the SmPC table.

Inclusion criteria

  • Mild to moderate allergic asthma

Links